Drug intelligence / Profile preview

RDH099

Development stage: Preclinical
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RDH099 is an investigational small molecule drug candidate developed by Apichope Pharmaceutical for the treatment of cardiovascular system diseases. Currently in the preclinical stage of development, the drug is being evaluated as an oral extended-release capsule formulation. While the specific mechanism of action and molecular target have not been publicly disclosed, the candidate is part of Apichope's innovative pipeline focusing on high-barrier formulations and optimized delivery systems for chronic disease management. The use of an extended-release profile suggests an intent to improve patient compliance and maintain stable therapeutic plasma concentrations.

Other names: RDH099 extended-release capsuleRDH-099 extended-release capsuleRDH 099 extended-release capsule

Beyond the preview

Go deeper on RDH099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RDH099.

Explore the full profile